Novozymes (CPSE:NSIS B) - Aktienkurs, Nachrichten und Analyse

NSIS B Aktienübersicht

NSIS B fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	3/6
Financial Health	4/6
Dividends	3/6

Belohnungen

Prognostiziertes Gewinnwachstum 18.23% pro Jahr

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Hat einen hohen Schuldenstand

Novozymes A/S Wettbewerber

Chr. Hansen Holding

CPSE:CHR

kr.72.3b

PPG Industries

NYSE:PPG

US$30.0b

Asian Paints

NSEI:ASIANPAINT

₹2.8t

EMS-CHEMIE HOLDING

SWX:EMSN

CHF17.1b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Novozymes
Historical stock prices
Current Share Price	kr.407.40
52 Week High	kr.438.00
52 Week Low	kr.274.60
Beta	0.51
1 Month Change	-6.43%
3 Month Change	-1.02%
1 Year Change	21.50%
3 Year Change	-12.65%
5 Year Change	34.15%
Change since IPO	1,157.41%

Aktuelle Nachrichten und Updates

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Feb 14

Is Novozymes A/S (CPH:NZYM B) Worth kr.537 Based On Its Intrinsic Value?

Jan 01

We Think Novozymes (CPH:NZYM B) Can Stay On Top Of Its Debt

Nov 28

Many Would Be Envious Of Novozymes' (CPH:NZYM B) Excellent Returns On Capital

Nov 11

Aktionärsrenditen

	NSIS B	DK Chemicals	DK Markt
7D	-3.0%	-3.3%	-0.8%
1Y	21.5%	2.6%	38.2%

Rendite im Vergleich zur Industrie: NSIS B übertraf die Branche Danish Chemicals, die im vergangenen Jahr eine Rendite von 3.6 erzielte.

Rendite vs. Markt: NSIS B hinter dem Markt Danish zurück, der im vergangenen Jahr eine Rendite von 36.8 erzielte.

Preisvolatilität

Is NSIS B's price volatile compared to industry and market?
NSIS B volatility
NSIS B Average Weekly Movement	3.5%
Chemicals Industry Average Movement	5.1%
Market Average Movement	4.4%
10% most volatile stocks in DK Market	10.0%
10% least volatile stocks in DK Market	2.9%

Stabiler Aktienkurs: NSIS B hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: NSIS BDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1925	6,577	Ester Baiget	www.novonesis.com

Novozymes A/S produziert und vertreibt industrielle Enzyme, Mikroorganismen und Probiotika in Dänemark, im übrigen Europa, in Nordamerika, im asiatisch-pazifischen Raum, im Nahen Osten, in Afrika, in Lateinamerika und international. Das Unternehmen bietet Proteinlösungen für die Lebensmittel- und Getränkeindustrie an. Es bietet auch industrielle Hygiene, Abflussöffner, harte Oberflächen, medizinische Reinigung, Klärbehälter, Geschirrspülen und professionelle Wäschereidienste.

Novozymes A/S's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Novozymes im Vergleich zum Marktanteil des Unternehmens?
NSIS B grundlegende Statistiken
Marktanteil	kr.189.28b
Gewinn(TTM)	kr.3.02b
Umsatz(TTM)	kr.17.90b

62.6x

Kurs-Gewinn-Verhältnis

10.6x

Kurs-Umsatz-Verhältnis

Ist NSIS B zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
NSIS B Gewinn- und Verlustrechnung (TTM)
Einnahmen	kr.17.90b
Kosten der Einnahmen	kr.8.18b
Bruttogewinn	kr.9.72b
Sonstige Ausgaben	kr.6.70b
Umsatz	kr.3.02b

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

Aug 28, 2024

Gewinn per Aktie (EPS)	6.51
Bruttomarge	54.32%
Nettogewinnspanne	16.89%
Schulden/Eigenkapital-Verhältnis	51.6%

Wie hat sich NSIS B auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.5%

Aktuelle Dividendenrendite

88%

Ausschüttungsquote

NSIS B Aktienübersicht

Belohnungen

Risikoanalyse

Novozymes A/S Wettbewerber

CPSE:CHR

kr.72.3b

NYSE:PPG

US$30.0b

NSEI:ASIANPAINT

₹2.8t

SWX:EMSN

CHF17.1b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Recent updates

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Erträge & Einnahmen